远端增强子RNA调控MYB可变启动子使用及白血病耐药
本研究在人类白血病细胞中鉴定出MYB -34 kb增强子区转录的两个双向增强子RNA:MY34UE-AS和MY34UE-S。两者均促进MYB转录、增殖与迁移,但分别通过不同启动子发挥作用。耐药白血病细胞中TSS2活性升高导致N端截短MYB表达增加,靶向MY34UE-AS比靶向MY34UE-S更有效缓解耐药,并在临床样本中验证了上述关系。
要点
- MY34UE-AS通过PURB介导-34 kb增强子与TSS2成环激活TSS2。
- MY34UE-S促进上游-34 kb增强子与TSS1成环激活TSS1。
- 耐药细胞中TSS2活性升高产生ΔN MYB,靶向MY34UE-AS更有效缓解耐药。
核心结论
- 首次阐明MYB启动子使用机制及MYB TSS2介导的人类白血病耐药机制。
- MY34UE-AS和MY34UE-S分别通过不同启动子促进MYB转录、增殖和迁移。
- 靶向MY34UE-AS比靶向MY34UE-S更有效缓解耐药。
研究设计与样本
- 在人白血病细胞中鉴定MYB -34 kb增强子区转录的双向增强子RNA MY34UE-AS和MY34UE-S。
- 在临床白血病样本中验证MY34UE-AS/MY34UE-S、TSS2/TSS1与预后的关系。
主要发现
- MY34UE-AS与PURB结合,促进下游-34 kb增强子元件与TSS2的长距离成环,激活TSS2。
- MY34UE-S促进上游-34 kb增强子元件与TSS1的DNA成环,促进TSS1转录。
- 耐药白血病细胞中TSS2活性升高而TSS1不变,总MYB不变时N端截短MYB(ΔN MYB)表达增加。
- ΔN MYB通过FTH1和EZH2通路比全长MYB更强地促进耐药。
关键数值与推荐
- MY34UE-AS和MY34UE-S均促进人白血病细胞增殖与迁移。
- 耐药细胞中TSS2活性升高,TSS1活性不变。
- 靶向MY34UE-AS比靶向MY34UE-S更有效缓解耐药。
临床怎么用
- 临床白血病样本中验证了MY34UE-AS/MY34UE-S、TSS2/TSS1与预后的关系。
- 靶向MY34UE-AS可能成为缓解白血病耐药的潜在策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
MYB is a master transcription factor for the hematopoietic system, and its dysregulation drives the development and therapy resistance of leukemia. However, the mechanisms of MYB regulation and MYB-related therapy resistance are still unclear. Here, we identified two bidirectional enhancer RNAs (eRNAs), MY34UE-AS and MY34UE-S, transcribed from the -34 kb enhancer region of MYB. Both eRNAs promote MYB transcription, proliferation, and migration in human leukemia cells, although through different MYB promoters. MY34UE-AS physically interacts with PURB that binds near MYB TSS2, promoting long-range looping between downstream -34 kb enhancer elements and TSS2, ultimately activating TSS2. While MY34UE-S facilitates DNA looping between upstream -34 kb enhancer elements and TSS1, promoting TSS1 transcription. TSS2, but not TSS1, activity increases in drug resistant leukemia cells, resulting increased expression of N-terminally truncated MYB (ΔN MYB) when total MYB remains unaltered. Compared to full-length MYB, ΔN MYB more potently promotes drug resistance through FTH1 and EZH2 pathway, and targeting MY34UE-AS more efficiently alleviates drug resistance than targeting MY34UE-S. The above relationship of MY34UE-AS/MY34UE-S, TSS2/TSS1, and prognosis was also verified in clinical leukemia samples. For the first time we provide the mechanisms underlying promoter usage of MYB and MYB TSS2 mediated drug resistance in human leukemia.
引用
- Wang Y, Wang X, Li M, et al. Distal enhancer RNAs regulate alternative promoter usage of MYB and drug resistance in human leukemia cells. Leukemia. 2026. PMID: 41571768. doi:10.1038/s41375-026-02862-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。